Cold Sore Virus: 3D Genome Weakness Found
- The common cold sore virus, herpes simplex virus-1 (HSV-1), doesn't just invade cells; it redecorates them.
- Esther González Almela, the study's frist author, said HSV-1 acts as an "opportunistic interior designer," precisely rearranging the human genome to access resources needed for reproduction.
- The researchers found that blocking the host enzyme topoisomerase I completely stopped HSV-1's ability to rearrange the human genome.
Herpes simplex virus-1 (HSV-1), the cold sore virus, doesn’t just attack; it actively remodels the human genome. This critical insight reveals HSV-1’s manipulation tactics, reshaping cellular architecture for replication. Scientists discovered HSV-1 acts as an “opportunistic interior designer,” using enzymes like topoisomerase I for genome rearrangement. Blocking this enzyme halts viral reproduction, presenting a targeted approach too antiviral treatments. Advanced imaging techniques provided real-time observation of HSV-1’s takeover. Affecting nearly 4 billion globally, finding new treatment strategies is paramount. News Directory 3 shares this breakthrough. Learn how this research could lead to more effective management of HSV-1 infections.Discover what’s next …
Cold Sore Virus Reshapes Human Genome for Replication
Updated June 22, 2025
The common cold sore virus, herpes simplex virus-1 (HSV-1), doesn’t just invade cells; it redecorates them. A new study reveals that HSV-1 actively reshapes the architecture of the human genome to enhance its own replication. This discovery,made by researchers at the Center for Genomic Regulation (CRG) in Barcelona,highlights a novel mechanism of viral manipulation.
Dr. Esther González Almela, the study’s frist author, said HSV-1 acts as an “opportunistic interior designer,” precisely rearranging the human genome to access resources needed for reproduction. This intentional reshaping distinguishes HSV-1 from other herpes viruses, where genome alteration was thought to be a mere side effect of infection.
The researchers found that blocking the host enzyme topoisomerase I completely stopped HSV-1’s ability to rearrange the human genome. ICREA Research Professor Pia Cosma, the study’s corresponding author, said inhibiting this enzyme in cell cultures prevented the virus from creating even a single new particle. This suggests topoisomerase I as a potential therapeutic target to combat the widespread virus.
Using advanced imaging techniques, including super-resolution microscopy and Hi-C, the team observed the viral takeover in real-time. Within an hour of infection,HSV-1 hijacks the human RNA-polymerase II enzyme to synthesize its own proteins. Enzymes like topoisomerase I and structural proteins then follow, leading to a collapse of transcription across the host genome.
Dr. Álvaro Castells García, co-first author, noted the unexpected finding that chromatin compaction occurred after transcription stopped, challenging previous assumptions about the relationship between genome structure and activity.
HSV-1 affects nearly 4 billion people globally, often causing asymptomatic infections or recurrent cold sores. Though, in rare cases, it can led to blindness or life-threatening illnesses, especially in newborns and immunocompromised individuals. The increasing rise of drug-resistant strains underscores the need for new treatment strategies.
What’s next
This research offers a promising avenue for developing new antiviral therapies targeting topoisomerase I, perhaps providing a more effective way to manage and control HSV-1 infections worldwide.